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Common memory aids for people with dementia at home are recommended.  However, rigorous 
evaluation is lacking, particularly what guidance or support is valued. 
 
OBJECTIVE 
To investigate effects of memory aids and guidance by Dementia Support Practitioners (DSPs) for 
people in early stage dementia through a pragmatic, randomised controlled trial. 
 
METHODS 
Of 469 people with mild to moderate dementia and their informal carers, 468 were randomised to a 
DSP with memory aids or to usual care plus existing dementia guide. Allocation was stratified by: 
Trust/Health Board; time since first attendance at memory service; gender; age; and living with 
primary carer or not.  Primary outcome was Bristol Activities of Daily Living Scale (BADLS) score at 3 
and 6 months (primary end-point).  Secondary outcomes for people with dementia: quality of life 
(CASP-19; DEMQOL); cognition and functioning (Clinical Dementia Rating Scale; SMMSE); capability 
(ICECAP-O); social networks (LSNS-R); and instrumental daily living activities (R-IDDD).  Secondary 
outcomes for carers: psychological health (GHQ-12); sense of competence (SSCQ). 
 
RESULTS 
DSPs were successfully trained, compliance was good and welcomed by participants.  Mean 6 
months BADLS score increased to 14.6 (SD 10.4) in intervention and 12.6 (SD 8.1) in comparator, 
indicative of greater dependence in the activities of daily living.  Adjusted between group difference 
was 0.38 (95% confidence interval -0.89 to 1.65, P=0.56).  Though this suggests greater dependency 
in the intervention group the difference was not significant.  No differences were found in secondary 
outcomes.   
 
CONCLUSIONS 
This intervention did not maintain independence in the activities of daily living with no improvement in 
































Dementia affects over 47 million people worldwide [1], with 850,000 people with dementia in 
the UK at any one time [2]. Numbers are predicted to increase, creating a challenge for 
health and care services to meet the needs of individuals living with the condition and their 
families [3]. Many people with dementia find it difficult to manage their day to day problems.  
Interventions to help them and their families manage these problems and difficulties can help 
to maintain functioning, and so independence from carer help, thus improving quality of life. 
To address this, the Lancet Commission on Dementia [4] recommended that interventions 
should be multi-component, individualised to need, support carers in their coping skills and 
modify the environment around the person with dementia.  Provision of memory aids, for 
those diagnosed with early-stage dementia, aiming to assist with daily living activities by 
sustaining cognitive and functional abilities [5, 6] and reducing carer burden [7] have been 
explored.  The use of these common, low-technology, aids, like calendars, clocks, 
whiteboards with electric timers, and “post-it” note dispensers, is widely recommended in 
clinical practice and by support organisations [8]; many are used by people with dementia at 
home, often with support from their family carers.  However, rigorous effectiveness 
evaluation is lacking, particularly of what guidance for using aids is valued, although people 
with dementia report a preference for such advice to be provided at home by a trained 
worker [9]. A Cochrane review [10] identified several studies reporting the usefulness of such 
memory aids or associated training, but they were small or low quality, with only two trials 
identified.  One trial [11] evaluated improvement in medication adherence from using an 
electronic pill dispenser, but although participants had memory impairment they had no 
validated dementia diagnosis. The ATTILA RCT [12], evaluated whether assistive 
technology and telecare assessments and interventions extend the time people with 
dementia may continue to live independently at home.  However, the interventions were not 
directed towards assistance with memory problems but rather safety concerns (for example 
provision of pendant alarms). This review therefore highlighted the need for a larger and 
more dedicated study, building on evidence from small-scale trials and other studies [13-17].   
The rationale for these aids is that they can help people with dementia overcome some of 
the effects of their memory problems so promoting achievement of daily living activities for 
longer.  In a context where memory is progressively deteriorating, the effectiveness of such 
memory aids would not be judged by improvements in cognition per se, but by the extent to 
which people with dementia may act more independently to attain their daily goals, for 
example keeping appointments and performing activities independently.  This is the domain 
in which the effects of such aids may be judged as successful or not - the proximal, or 
targeted outcome that such interventions are designed to impact upon following completion.  
There may be further distal outcomes from use of such aids; the person may be less 
agitated or confused, and may experience a better quality of life; and their informal carers 
may experience less burden [18, 19]. 
The Dementia Early Stage Cognitive Aids New Trial (DESCANT), a multi-site, pragmatic 
randomised trial, tested the effectiveness of this approach on relevant outcomes for people 
with dementia and their carers.  We implemented and evaluated the effectiveness of 
guidance by Dementia Support Practitioners (DSPs) to support people with early-stage 
dementia and their carers in using memory aids at home, relative to treatment as usual 
(TAU).  We designed the intervention to be relatively inexpensive, realistic and scalable [20] 







This trial was preceded by a feasibility study and internal pilot. Randomisation allocation was 
in equal proportions between intervention and comparator groups.  We recruited people with 
mild to moderate dementia with an identified primary carer – from memory services within 10 
Health Trusts/Boards across England and Wales. Trained DSPs delivered the interventions 
in participants’ homes.  
 
Trained interviewers assessed the capacity to consent of potential participants according to 
the principles of the Mental Capacity Act (2005).  We asked those judged to have capacity 
for their written informed consent. For those judged to lack capacity, we asked their primary 
carer or a personal consultee about their whether the person would have consented and 
asked that person to provide written consent on their behalf.  
 
Carers gave written informed consent to provide data about the person with dementia. We 
checked their agreement to continue participation at each visit.  We also undertook 
interviews with carers to investigate their own outcomes, for which they provided separate 
written informed consent. 
 
Participants 
Eligibility criteria for people with dementia were; diagnosed dementia of mild to moderate 
severity; aged 50 years or more; under the care of a trial memory clinic; within one year of 
their first attendance for dementia; physically (judged from medical records) and clinically 
(judged by a responsible clinician) able to engage with the intervention, for instance able to 
hold, view and use the memory aids and be sufficiently able to interact with the DSP; living in 
their own home or sharing with a relative; and having an identified carer, defined as the primary 
person who feels responsible and supports them.   
 
Study treatments 
Our trial protocol describes the intervention and rationale [21]. The 4-week intervention 
aimed to improve the abilities, functioning and independence of people with early-stage 
dementia and their carers, by providing a range of memory aids, and training and support in 
their use.  Dementia Support Practitioners (DSPs) delivered the intervention using a manual 
(https://sites.manchester.ac.uk/home-support-dementia/) to guide each of the four sessions, 
with worksheets to facilitate and record delivery (‘Intervention record’). The aim was to 
deliver the first session face-to-face at home to participant pairs within two weeks of 
randomisation. During this session DSPs collected information about memory problems, 
current use of memory aids, and what goals participants would like to achieve by 
participating, using standardised and study specific worksheets [22]. DSPs provided an 
appropriate pack of memory aids and support at the first session. They used core memory 
aids: whiteboard; clock showing day and date; post-it notes; pen and notepad; and calendar. 
These were selected as they are readily available, were simple to install, and are relatively 
inexpensive. DSPs also had the flexibility to purchase more items within a budget of £150 
per participant to tailor their intervention to individual goals. Additionally, they could also 
provide support with memory aids already in use within the home. Two telephone follow-up 
support sessions and a final session face to face at home with participants and their carers 
were undertaken by DSPs. Whilst the first and fourth sessions were a core part of the 
intervention, intermediate support sessions—telephone or face-to-face to deliver or adjust a 
memory aid—were optional. A reflection of the fact that this was a personalised intervention, 
throughout there was flexibility for participants, people with dementia or carers, to meet the 
DSP jointly or separately if they wished, and it was recognised that the extent of participation 
in each session could vary depending on the preferences of the person with dementia and 




All participants received usual care from memory clinics, in accordance with clinical 
guidance.  This comprised help from clinic staff, post-diagnostic counselling and advice, and 
specialist follow up as appropriate.  
 
Data collection 
We trained clinical staff in participating sites.  They completed a screening tool to check 
participant eligibility, gave a participant information sheet to eligible participants, and sought 
oral consent to refer them to the DESCANT team. We collected baseline data from outcome 
questionnaires before randomisation and followed all participants up three and six months 
after randomisation. The research team checked the quality of these data. 
 
Outcomes for people with dementia 
The primary outcome at 6 months was the carer-rated Bristol Activities of Daily Living Scale 
(BADLS) [23], representing independence in the activities of daily living; scored 0 to 60 with 
higher scores showing worse impairment.  Secondary outcomes at 3 and 6 months after 
randomisation were: Control, Autonomy, Self-realisation and Pleasure 19-item (CASP19) 
[24], scored 0 to 57 with higher scores showing better quality of life; Clinical Dementia Rating 
scale (CDR) [25], scored 0-3 with higher scores showing worse cognitive and behavioural 
functioning; Dementia Quality of Life (DEMQOL [26], scored 28 to 112 with higher scores 
showing better quality of life; Investigating Choice Experiments for the Capability of Older 
people (ICECAP-O) [27], scores between 0 (no capability) to 1 (full capability); Lubben 
Social Network Scale – Revised (LSNS-R) [28], scored 0 to 60, with higher scores showing 
more social engagement; Revised Interview for Deterioration in Daily Living Activities in 
Dementia (RIDDD [29], with Initiative scoring between 0 and 60, Performance scoring 
between 0 and 76 and higher scores showing greater impairment; and the Standardised 
Mini-Mental State Examination (S-MMSE) [30], scored between 0 and 30 with lower scores 
showing worse cognitive impairment.  To estimate use of health and social care resources 
we completed the Client Services Receipt Inventory [31] and Resource Utilisation in 
Dementia questionnaire [32]. The interviews took about one and a half hours [33]. 
 
Outcomes for carers 
Secondary outcomes for carers were the General Health Questionnaire (GHQ-12) [34], 
scoring between 0 and 36 with higher scores showing worse health and the Short Sense of 
Competence Questionnaire (SSCQ) [35], scoring from 7 to 35 with higher scores showing 
greater competence. 
 
Randomisation and masking 
Trial managers coordinated recruitment and forwarded participants’ details to the trials unit’s 
email-based randomisation service. After baseline interviews, the unmasked trial data 
manager oversaw randomisation, which allocated participants in equal proportions between 
intervention and comparator groups, stratified by: Trust or Health Board (one of 10); time 
since first attendance at memory clinic (more or less than 90 days); gender (male or female); 
age (more or less than 75 years); and living with primary carer or not.  Allocation between 
groups used dynamic software to randomise participants in real time, thus preventing 
subversion while ensuring (stochastic) balance between groups [36].  Participants then 
received a letter specifying their allocated group and reminding them what this entailed. 
Participants in the comparator group received a general guide to dementia [8]. Participants 
in the intervention group received invitations to arrange initial visits by the DSP within 2 
weeks of randomisation. 
 
Masking participants, carers, or DSPs was not possible. Researchers conducting baseline 
and follow-up interviews were masked to treatment condition and participants were asked 
not to disclose the group they were allocated to. In this way, interviewers were kept masked 
as much as possible, although we also asked them to indicate what group they believed the 





We calculated that an analysable sample of 360 (180 in each group) across participating 
sites would yield 80% power to detect an effect size (standardised mean difference) of 0.30 
on BADLS, using a two-sided significance level of 5%.  To allow for 25% attrition (estimated 
from previous studies [37]) between baseline and final interviews, we aimed to randomise 
480 pairs of people with mild to moderate dementia and their carers. 
 
Statistical Analysis 
Analysis followed a statistical analysis plan approved by our Data Monitoring and Ethics 
Committee (DMEC) before data were accessed.  We analysed data on all participants by 
treatment allocated. Analyses were done in Stata V.16.  We present descriptive statistics, by 
group, for baseline characteristics of participants randomised and in the primary analysis.  
To characterise the effect of the intervention over time, we fitted multi-level mixed-effect 
models, as these take better account of missing data, especially if missing at random, and 
explicitly account for correlations between repeated measurements within each participant 
[38].  Analyses by treatment allocated estimated the effect of the intervention on participants 
by adjusting for baseline differences in the measure under analysis, participant 
characteristics (viz. Trust/Health Board, age, gender and ethnicity), time since first 
attendance at memory clinic or equivalent, whether living with primary carer or not, and the 
time to follow up.  We followed this plan both in primary analysis of BADLS and secondary 
analyses of all other outcomes.   
 
We excluded participants without any follow-up data from the main analyses. We followed 
published rules for imputing missing data for individual outcome measures. To investigate 
the potential effects of missing data on the primary outcome, we performed a multiple 
imputation with Markov Chain Monte Carlo (MCMC) procedures. This, the most common 
parametric approach for multiple imputation, assumes that all the variables in the imputation 
model have a joint multivariate normal distribution.  We undertook sensitivity analysis 
comparing estimates with and without imputation.  
 
Study monitoring 
A Trial Management Group (TMG) monitored compliance with the study protocol, operating 
procedures and liaised with Trusts/Boards to recruit participants.  The TMG oversaw and 
resolved operational issues, and reported to the DMEC, the Programme Steering Committee 
and the funder.   
 
To ensure the intervention and research methods worked in practice, we completed an 
internal feasibility study and pilot with 40 participants recruited from the two initial host Trusts 
in equal numbers, in August 2017.  We adapted the Acceptance Checklist for Clinical 
Effectiveness Pilot Trials (ACCEPT) criteria [39] to assess whether the intervention and trial 
protocol worked in practice, and the DMEC accepted these criteria. The decision from the 
pilot was that the design and methods were feasible and appropriate and that the 
intervention training and procedures were acceptable, to DSPs and participants. DSPs 
considered the available budget to be feasible to fund necessary items. Despite their low 
cost they found the aids to potentially permit individualised responses to identified needs.  
Participants valued the strategies and advice from DSPs in tandem with the provision of 
aids. Participants provided positive feedback to DSPs about the memory aids, particularly 
the orientation clock, whiteboards and calendars. People with dementia reported reduced 
reliance on their carer and carers the opportunity to discuss dementia and its impact [22].  
The only adjustment suggested by the pilot was to reduce the length of follow up from the 
initially planned 12 months to 6 months for the main study.  This enabled us to meet 
recruitment targets and tackle the more realistic goal of improving BADLS scores over 6 
months. Thus, we included the pilot data, adjusted to reflect this change, in the main 
analyses. The University of Manchester as Sponsor approved this modification and we 
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communicated this to the National Research Ethics Service who approved the original 
protocol, sites and participants. 
 
The DMEC could halt the trial for safety or ethical concerns.  Only the DMEC had access, 
through the trial data manager, to un-blinded data before the trial ended in November 2019 
and they approved the blinded primary analysis.    
 
Patient and carer involvement 
We involved people with dementia and their carers through a Public, Patient and Carer 
Reference Group (PPCRG), in North West England and a Lay Advisory Panel across the 
country, established through Together in Dementia Everyday (TIDE), a national charity 
advocating on behalf of carers of people with dementia.  The PPCRG helped specify 
research questions, select outcome domains and design the intervention, including guidance 
given to the comparator group.  The PPCRG also advised on data collection procedures, 
patient facing materials and on strategies to boost recruitment.  Carers of people with 




Trial progression and recruitment 
We recruited participants incrementally over 3 years, with sites added from the support to 
recruitment provided by the infrastructure of the funder, the National Institute for Health 
Research in England.  Figure 1 shows that between 25/11/16 (first participant enrolled on 
6/12/16) and 25/11/19 (when data were locked for analysis), we screened 4426 people, 
found 1680 potentially eligible and recruited 470; as one participant missed the home visit 
and thus informed consent and another withdrew before randomisation, we randomised 468 
– 234 to the intervention and 234 to usual care.  Four (2%) participants died in the 
intervention group and 6 (3%) in the comparator.  The mean (SD) duration of intervention 
visits was 94 minutes (29) for the first visit, 17 (11) for first follow up, 17 (16) for second 
follow up, and 55 (25) for the final review [22].  The intervention followed at a mean (SD) of 
15 (11) days after randomisation.  The mean (SD) number of days between first and last 
sessions was 26 (9).  In total 121 participants (58 intervention and 63 comparator) withdrew: 
75 actively withdrew (31 intervention and 44 comparators); 31 were lost to follow up (19 
intervention and 12 comparators); one participant withdrew following a Serious Adverse 
Event unrelated to the intervention; and one for another reason (both intervention). Ten 
participants died (four intervention and six comparators), and reasons were missing for three 
participants (two in the intervention arm).   
 
Sample 
The 468 randomised participants was slightly fewer than the 480 estimated as needed to 
achieve our analysis target of 360, to allow for attrition characteristic of recruitment in this 
vulnerable population.  Attrition at 6 months was slightly higher than expected (26% rather 
than 25%), so the number of participants for primary analysis, with data at baseline and 6 
months, was 347, also slightly lower than target.  Baseline characteristics of the randomised 
and analysed samples were well-balanced (Table 1).  The average age of those with 
dementia was around 80 years, with slightly more females.  At referral, 376 people (80%) 
with dementia were able to provide informed consent; the remaining 92 (20%) needed a 
consultee.  Table 1 shows baseline characteristics of randomised and analysed participants. 
 
Intervention 
DSPs in each of the 10 Trusts/Health Boards delivered the intervention to people with 
dementia and their carers.  A sample of 126 intervention records  [22] showed good 
engagement with almost all participants (98%) fully completing the sessions, delivered as 
planned with packages individually tailored to participants’ preferences.  The mean interval 
between randomisation and the first home visit, the duration of visits, and the total duration 
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of the intervention, were consistent with study protocol.  Variations in delivery typically 
reflected participants’ goals and preferences (e.g. time of day, availability of a carer) and 
DSP availability.  Misplacement of items and orientation to date and time were common 
areas of need.  Memory aids frequently supplied or supported included orientation clocks, 
whiteboards, calendars and notebooks as well as bespoke items.  The intervention was 
acceptable, with little negative feedback.  Unforeseen benefits included the recognition of 
undiagnosed memory issues in a family member and the use of memory aids by other family 
members to coordinate care [22].   
 
Resource use 
At baseline health and social care resource use differed between arms: more people with 
dementia in the intervention group had been inpatients on general medical wards (online 
supplemental Table A1).  Some participants already had memory aids at home, notably 
clocks or medication reminders, but without guidance from a DSP; this existing use of aids 
did not differ between groups. At six months, more intervention participants had received 
visits from a social worker, dementia support worker or health visitor; or been admitted to 
general medical wards.  More participants in the usual care group had received aids, 
adaptations or equipment at follow up.  We report cost-effectiveness of the intervention 
elsewhere [40].   
 
Serious Adverse Events 
There were 43 Serious Adverse Events (SAEs) in 42 participants (24 intervention and 18 
comparators).  One comparator experienced two SAEs, both falls.  People with dementia 
experienced 36 of these SAEs.  No SAE was definitely, probably or possibly related to the 
intervention. Eight SAEs resulted in death (4 in intervention arm, 4 in comparator); three 
were life threatening (1 intervention, 2 comparator); two caused persistent or significant 
disability or incapacity (both intervention); one comparator suffered another medically 
important condition; and 29 were hospitalised (17 intervention, 12 comparator).    
 
Outcomes 
Table 2 shows the main treatment effect estimates for the primary outcome.  The 
intervention group began with higher unadjusted BADLS scores (showing more 
dependency), which stayed constant at 3 months, but showed a marked increase to 
significantly higher dependency than the comparator group at 6 months. This significance 
was due in part to higher BADLS scores in comparators who were lost to follow-up or died 
between baseline and 6 months.   
 
The multi-level mixed-effects models showed no significant differences between arms over 
time (Table 3 and Figure 2) in BADLS, the primary outcome.  Outcomes in both groups 
reflected increasing dependency over time in activities of daily living.  BADLS scores, 
showed a mean difference of only 0.38 at 6 months, slightly but not significantly favouring 
the comparator group (95% confidence interval from -0.89 to 1.65, p=0.56).  There were no 
significant differences between groups for all other patient-reported and carer reported 
outcomes (Table 4 presents summary data; Tables A2-A11 present full data for each).   
 
Sensitivity analyses for the primary outcome, BADLS, accounting for missing data showed 
no differences in outcome estimates with and without imputation (appendix, Table A12; 
Figure A1). 
 
At 6 months, interviewers indicated they knew treatment assignment in 33/234 cases (14%) 
in the usual care arm and 82/234 (35%) in the intervention arm (overall 25 %).  Including 






Our four-week programme, in which DSPs added to usual care by offering guidance in the 
use of memory aids at home, did not improve independence in the activities of daily living for 
people with mild to moderate dementia. We implemented the intervention as planned, and 
people with dementia and their carers welcomed it.  But that did not translate into 
improvements in independence in activities of daily living, quality of life, or in carers’ 
outcomes.  
 
Comparison with previous studies 
These results are less positive than some other studies [41, 42], but those studies are 
smaller and in single centres.  Furthermore, those interventions were not as well designed 
and included little dedicated training.   Some previous studies investigated provision of 
memory aids and training and concluded that these helped with everyday memory.  One trial 
of a memory aids service [43] compared a three-session six-week clinic programme with 
waiting list controls for people with neurological conditions.  This benefited participants’ 
everyday memory goals if they had a non-progressive condition; but did not measure 
activities of daily living.  There were no benefits for those with progressive conditions, like 
dementia.  That study concluded that more than three training sessions were needed for 
those with progressive memory problems. Another trial [41] reported training in using a 
notebook/calendar system for participants with mild cognitive impairment and found 
beneficial effects on activities of daily living.  However, this recruited only 40 participants and 
excluded participants with dementia.  A trial of cognitive rehabilitation for people with early-
stage Alzheimer disease [42], including practical aids and strategies to assist memory, found 
improved goal performance and satisfaction, but randomised only 69 participants.   
 
Strengths and limitations  
We improved upon previous studies by including systematic training and record-keeping, 
and an extended number of sessions in participants’ homes – a familiar environment most 
likely to yield benefit. We delivered the intervention as planned, with good compliance by 
participants and carers.  Compared with other trials we recruited a much larger sample and 
covered a greater geographical spread. Our analysis of both observed and fully imputed 
data, taking account of missing data, yielded similar estimates of treatment effects on 
activities of daily living.   
 
Though we could not mask participants and carers to treatment allocation, masking was 
neither feasible nor desirable.  Recruiting enough people with dementia living at home is 
challenging for all such trials.  Though our sample was slightly smaller than target, and our 
analysis slightly underpowered, we found no hint of benefit.   
 
Interpretation 
Our intervention was implemented successfully [22], with high compliance and delivery as 
planned.  Following several small studies, we aimed to improve independence in activities of 
daily living by using DSPs to deliver memory aids to participants’ homes, and guide their 
use.  Our pre-specified effect size, used in our sample size calculation, corresponded to a 
3.5 minimum clinically important difference on BADLS, with a standard deviation of 8.7 [44]  
However, we found an adjusted average effect of only 0.38, with dependency in the activities 
of daily living increasing over time, consistent with published evidence [45].  Any slowing of 
that dependency is a valuable consequence of care with tertiary prevention a legitimate aim 
[4].  But the intervention did not achieve that aim.  It may be that this kind of practical 
intervention may be useful much earlier in the course of dementia in promoting 
independence, even before diagnosis when abilities have not deteriorated to the same 
extent.  However, assistance like this cannot be accessed earlier in existing service systems 
(at least in the UK) as diagnosis is the gateway to receiving such formal, tailored support.  
However, it could also be that the 4-week duration of this intervention was insufficient to 





A dedicated practitioner to guide and advise on the use of memory aids cannot be 
recommended as a care option to maintain independence in activities of daily living in people 
with dementia. In future, similar trials should investigate other outcomes valued by people 
with dementia, for example engagement and other, more subtle effects, such as increased 
confidence, enhanced relationships, feeling valued and respected, not yet measured in trials 
[46]. The effectiveness of offering other types of guidance needs investigation with such 
outcome measures.  However, this intervention was not an effective way to manage daily 





A four-week programme of advice, guidance and support in using memory aids, did not 
increase independence in activities of daily living in people with mild to moderate dementia. 
Although well received and providing reassurance in other areas, such as enhanced 
information for carers and advice as to unmet needs, it did not improve the outcomes 





1- World Health Organization. The epidemiology and impact of dementia. Current state and 
future trends. World Health Organisation, 2015.  
2- Prince M, Knapp M, Guerchet M, et al. Dementia UK: Update. Alzheimer’s Society, 2014.  
3- Department of Health. Prime Minister's challenge on dementia 2020. Department of 
Health, 2020. 
4- Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and 
care. Lancet 2017; 390(10113): 2673-734. 
5- Clare L, Kudlicka A, Oyebode JR, et al. Individual goal‐oriented cognitive rehabilitation to 
improve everyday functioning for people with early‐stage dementia: A multicentre 
randomised controlled trial (the GREAT trial). Int J Geriatr Psychiatry 2019; 34:709-21.    
6- Gillespie A, Best C, O'Neill B. Cognitive function and assistive technology for cognition: A 
systematic review. J Int Neuropsychol Soc 2012; 18:1-9. 
7- McHugh JE, Wherton JP, Prendergast D, Lawlor BA. Identifying opportunities for 
supporting caregivers of persons with dementia through information and communication 
technology. Gerontechnology 2012; 10:220-30. 
8- Alzheimer’s Society. The memory handbook: a practical guide to living with memory 
problems. Alzheimer’s Society, 2014; 
https://www.alzheimers.org.uk/sites/default/files/2020-
03/The%20memory%20handbook%201540.pdf 
9- Chester H, Clarkson P, Davies L, et al. Patient and carer preferences for home support 
services in early stage dementia. Ageing Mental Health. 2016; 22: 270-79. 
10- Van der Roest HG, Wenborn J, Pastink C, Dröes R-M, Orrell M. Assistive technology for 
memory support in dementia. Cochrane Database Syst Rev 2017; 6:CD009627-CD. 
https://doi.org/10.1002/14651858.CD009627.pub2 
11- Ownby RL, Hertzog C, Czaja SJ. Tailored information and automated reminding to 
improve medication adherence in Spanish‐ and English‐speaking elders treated for 
memory impairment. Clinical Gerontologist 2012;35(3):221‐38. 
12- Gathercole R, Bradley R, Harper E, et al. Assistive technology and telecare to maintain 
independent living at home for people with dementia: the ATTILA RCT. 
13- Lauriks S, Reinersmann A, Van der Roest HG, et al. Review of ICT-based services for 




14- McGrath, M, Passmore, P. Home-based memory rehabilitation programme for persons 
with mild dementia. Ir J Med Sci 2009; 178 (suppl 8); S330. 
15- Topo P. Technology studies to meet the needs of people with dementia and their 
caregivers: a literature review. Journal of Applied Gerontology 2008; 28:5-37.  
16- Meiland F, Innes A, Mountain G, et al. Technologies to support community-dwelling 
persons with dementia: a position paper on issues regarding development, usability, 
effectiveness and cost-effectiveness, deployment, and ethics. JMIR Rehabil Assist 
Technol 2017; 4(1):e1. 
17- Gibson G, Newton L, Pritchard G, Finch T, Brittain K, Robinson L. The provision of 
assistive technology products and services for people with dementia in the United 
Kingdom. Dementia 2016; 15:681-701. 
18- Cahill S, Macijauskiene J, Nygård A‐M, Faulkner J‐P, Hagen I. Technology in dementia 
care. Technology and Disability 2007;19(2):55‐60. 
19- Chester H, Beresford R, Clarkson P, et al. The Dementia Early Stage Cognitive Aids 
New Trial (DESCANT) intervention: A goal attainment scaling approach to promote self-
management. Int J Geriatr Psychiatry 2021 May;36(5):784-793. doi: 10.1002/gps.5479. 
Epub 2020 Dec 15. 
20- Ministerial Advisory Group on Dementia Research. Final report from the MAGDR 
subgroup 1 on priority topics in dementia research. MRC, 2011. 
21- Chester H, Clarkson P, Davies L, et al. Cognitive aids for people with early stage 
dementia versus treatment as usual (Dementia Early Stage Cognitive Aids New Trial 
(DESCANT)): study protocol for a randomised controlled trial. Trials 2018; 19:546, 
https://doi.org/10.1186/s13063-018-2933-8  
22- Chester H, Beresford R, Clarkson P, et al. Implementing the Dementia Early Stage 
Cognitive Aids New Trial (DESCANT) intervention: mixed-method process evaluation 
alongside a pragmatic randomised trial. Aging Mental Health 2020; 1-13. 
23- Bucks RS, Ashworth DL, Wilcock GK, Siegfried K. Assessment of activities of daily living 
in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing 1996; 
25:113-20.  
24- Hyde M, Wiggins RD, Higgs P, Blane DB. A measure of quality of life in early old age: 
The theory, development and properties of a needs satisfaction model (CASP-19). Aging 
Mental Health 2003; 7:186–94. 
25- Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the 
staging of dementia. Br J Psychiatry 1982; 140: 566–72. 
26- Smith SC, Lamping DL, Banerjee S, et al. Measurement of health related quality of life 
for people with dementia: development of a new instrument (DEMQOL) and an 
evaluation of current methodology. Health Technol Assess 2005; 9:10. 
27- Coast J, Flynn TN, Natarajan L, Valuing the ICECAP capability index for older people. 
Soc Sci Med 2008; 67: 874–82. 
28- Lubben J, Gironda M. Centrality of social ties to the health and well-being of older adults. 
In: Berkman B, Harooytan L, (eds). Social work and health care in an aging world. 
Springer, 2003; 319–50. 
29- Giebel CM, Challis D, Montaldi D. A revised interview for Deterioration in Daily activities 
in Dementia (R-IDDD) reveals the relationship between social activities and well-being. 
Dementia 2016; 15:1068–81. 
30- Molloy D, Standish T. Mental status and neuropsychological assessment: a guide to the 
Standardised Mini-Mental State Examination. Int Psychogeriatr 1997; 9: 87–94. 
31- Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, Brewin CR, 
Wing J, (eds). Measuring mental health needs. Gaskell, 1992. 
32- Wimo A, Wetterholm AL, Mastey V, Winblad B. Evaluation of the healthcare utilisation 
and caregiver time in anti-dementia drug trials – a quantitative battery. In: Wimo A, 
Jonsson B, Karlsson G, Winblad B, (eds). Health economics of dementia. Wiley, 1998. 
15 
 
33- Abendstern M, Davies K, Poland F. et al. Reflecting on the research encounter for 
people in the early stages of dementia: Lessons from an embedded qualitative study. 
Dementia 2019; doi: 10.1177/1471301219855295. 
34- Goldberg DP. Manual of the General Health Questionnaire. NFER-Nelson, 1978. 
35- Vernooji-Dassen M, Felling A, Brummelkamp E, Dauzenberg M, van den Bos G, Grol R. 
Assessment of caregiver’s competence in dealing with the burden of caregiving for a 
dementia patient: a short sense of competence questionnaire (SSCQ) suitable for clinical 
practice. J Am Geriatr Soc 1997; 47:256–7. 
36- Russell D, Hoare ZSJ, Whitaker R, Whitaker CJ, Russell IT. Generalised method for 
adaptive randomisation in clinical trials. Stat Med 2011; 30:922–34. 
37- Clarkson P, Venables D, Hughes J, Burns A, Challis D. Integrated specialist assessment 
of older people and predictors of care-home admission. Psychological Medicine 2006; 
36: 1011–1021.  
38- Detry MA, Ma Y. Analyzing repeated measurements using mixed models. JAMA 2016; 
315:407-8.  
39- Charlesworth G, Burnell K, Hoe J, Orrell M, Russell I. Acceptance checklist for clinical 
effectiveness pilot trials: a systematic approach. BMC Medical Research Methodology 
2013; 13:78.   
40- Clarkson P, Challis D, Hughes J, Roe B, Davies L, Russell I, et al. Components, impacts and 
costs of dementia home support: a research programme including the DESCANT 
RCT. Programme Grants Appl Res 2021;9(6) 
41- Greenaway MC, Duncan NL, Smith GE. The memory support system for mild cognitive 
impairment: Randomized trial of a cognitive rehabilitation intervention. Int J Geriatr 
Psychiatry 2012; 28:402–09. 
42- Clare L, Linden DEJ, Woods RT, et al. Goal-oriented cognitive rehabilitation for people 
with early-stage Alzheimer disease: A single-blind randomized controlled trial of clinical 
efficacy. Am J Geriatr Psychiatry 2010; 18:928–39. 
43- Dewar BK, Kapur N, Kopelman M. Do memory aids help everyday memory? A controlled 
trial of a memory aids service. Neuropsychological rehabilitation 2018; 28:614-32. 
44- Howard R, Phillips P, Johnson T, et al. Determining the minimum clinically important 
differences for outcomes in the DOMINO trial. Int J Geriatr Psychiatry 2011; 26:812–17. 
45- Giebel CM, Sutcliffe C, Challis D. Activities of daily living and quality of life across 
different stages of dementia: a UK study. Aging Mental Health 2015; 19:63-71.  
46- Harding AJE, Morbey H, Ahmed F, et al. A Core Outcome Set for non-pharmacological 
community based interventions for people living with dementia at home: a systematic 























































a Though final follow up was originally at 12 months, the DMEC agreed to reduce this to 6 months after the pilot.  
 
Fig 1. Flowchart for participants through the DESCANT trial. PWD = person with dementia 
 
2746 PWD missed 
referral form 
Service completes referral form for 1680 
PWD 
597 PWD failed 
inclusion criteria; 
613 did not consent 
470 PWD who meet inclusion criteria receive 
Participant Information Sheet, and consent to 
home visit 
 1 PWD lost 
from home 
visit/consent n=1 
469 home visits by researcher 
to take consent  
and complete baseline data 
1 PWD not 
randomised 
Randomise 468 consented participants 
between Intervention & Comparator Groups 
Allocation 
234 to Intervention Group 234 to Comparator Group 
 
193 (83%) followed at 3 months 
176 (75%) followed at 6 monthsa 
 
178 (76%) followed at 3 months 
171 (73%) followed at 6 monthsa 
31 withdrew, 19 lost to follow-up, 
4 died, 2 lost for other reasons, 
2 lost for reason not recorded 
44 withdrew, 12 lost to follow-up, 
6 died, 0 lost for other reasons, 
1 lost for reason not recorded 
Analysed at primary end point, n=176 Analysed at primary end point, n=171 
4426 People diagnosed with early-stage 





Table 1 Baseline characteristics of randomised participants (people with dementia) and 
those providing data for analysis of the primary end point (BADLS score at 6 months) by arm 
 










Mean (95% CI) age (years) 
Median  





























Female   
  
112 (48%)  
122 (52%)  
  
108 (46%)  








White   
Non-White 
  
211 (90%)  
23 (10%)  
  
216 (92%)  







Marital Status:  
Single  
Married or cohabiting  




10   (4%)  
152 (65%)  
9   (4%)  
62 (26%)   
1 (0.4%)  
  
4 (2%)  
150 (64%)  
18 (7%)  














Usually living:  
Own home with partner   
Own home with carer  
Own home alone  
Supported accommodation  
Other   
  
148 (63%)  
12   (5%)  
60 (26%)  
7   (3%)  
7   (3%)  
  
144 (61%)  
13   (6%)  
61 (26%)  
6   (3%)  













Accommodation Types  
Owner occupied  
Privately rented   




195 (83%)  
13   (6%)  
 
23 (10%)  
3   (1%)  
  
199 (85%)  
9   (4%) 
  
23 (10%)  













Living with Primary Carer 
Not living with Primary Carer 
147 (63%)  
87 (37%) 
148 (63%)  
86 (37%) 




<90 days since 1st Memory 
Clinic 










Male carer N (%) 73 (31.2) 73 (31.2)  58 (33.92) 62 (35.2) 
Mean (SD) carer age (years) 65.9 (13.22) 66.3 (13.44)  68.1 (12.93) 67.2 (13.08) 
Mean (SD) BADLS score 12.12 (8.8)  11.5 (8.5)  11.98 (9.0) 10.04 (7.5) 










Table 2 Unadjusted findings for BADLS (primary outcome) by arm 




Baseline   
n   
Mean (95% CI)  
Median  
SD  
Missing (%)  
  
234  






















3 Months  
n   
Mean (95% CI)  
Median  
SD  
Missing (%)  
  
193  
12.1 (10.9,13.4)  
10.0  
8.9  
41 (17.5)  
  
178  
11.6 (10.1,12.9)  
10.0  
9.7  






98 (20.9)  
  
 







6 Months  
n   
Mean (95% CI)  
Median  
SD 
Missing (%)  
  
176  
14.6 (13.1,16.2)  
12.5  
10.4  
58  (24.8)  
  
171  
12.6 (11.4, 13.8)   
12.0  
8.1  
63 (26.9)  
  
347  
13.6 (12.6,14.6)  
12.0  
9.3  
121 (25.9)  
  
 





SD = Standard deviation, CI = Confidence Interval;  
Bristol Activities of Daily Living Scale (BADLS): scores from 0 to 60; higher scores show greater dependence.  
BADLS Score: ranges 0 (totally independent) to 60(totally dependent); higher scores indicates greater dependency  























Here N’s are: 468, 371 and 347 for the three time points respectively 
 
















Table 3 Adjusted (multi-level mixed model) estimates for primary outcome, BADLS: 
coefficients  




95% CI  (B)  z  p-value  
Treatment arm:   
Intervention  
Comparator 0.70  -0.94, 2.34 0.84  0.40  































0.00*   
Gender (Female) Male -0.18 -1.77, 1.41 -0.22    0.83 
Ethnicity (Non-White) White 3.50 0.64, 6.38 2.40 0.02* 
≥ 90 days since 1st 
attended Memory Clinic 
< 90 days -0.95 -2.76, 0.87 -1.02 0.31 
Living with Primary Carer No 0.49 -1.25, 2.22 0.55 0.58 
*p < 0.05 
Bristol Activities of Daily Living Scale (BADLS): scores from 0 to 60; higher scores show greater dependence. 
Intraclass Correlation Coefficient (ICC) for ‘Trust’ = 0.01 
We fitted a multi-level mixed-effect model with all the above covariates as fixed-effect and intercept as random 
effect.  





















Table 4 Adjusted (multi-level mixed model) estimates for secondary outcomes: coefficients  
Outcomes 1 Coefficient (B)  95% CI  (B)  z  p-value  
CASP192  -0.04 -1.40, 1.32 -0.06 0.95 
CASP193 -0.07 -1.42, 1.28 -0.10 0.92 
CDR -0.14 -0.82, 0.53 -0.43 0.67 
DEMQOL 0.13 -2.29, 2.55 0.11   0.92 
LSNS-R -0.89 -2.71, 0.92 -0.96 0.34 
RIDDD Initiative 0.89 -2.03, 3.82 0.60 0.55 
RIDDD Performance -0.77 -3.66, 2.11 -0.53 0.60 
S-MMSE -0.20 -1.08, 0.68 -0.45 0.70 
GHQ-12 -0.38 -1.32, 0.55 -0.81 0.42 
SSCQ -0.43 -1.46, 0.59 -0.83 0.40 
*p < 0.05 
Ns respectively for T1; T2; T3 are: CASP 19a (451; 358; 322); CASP 19b (467; 365; 342); CDR (466; 370; 347; 
DEMQOL (446; 350; 323; LSNS-R (468; 369; 346); RIDDD Initiative (465; 365; 342); RIDDD Performance 
(466; 368; 343); S-MMSE (466; 367; 340); GHQ-12 (468; 369; 344); SSCQ (468; 368; 343). 
 
1 Estimates are for treatment arm with the comparator group as the reference category 
2CASP19 by the patients 
3CASP19 by the Carer 
Intraclass Correlation Coefficient (ICC) for ‘Trust’ =  CASP192(0.000), CASP193(0.003), CDR(0.02), DEMQOL 
(0.000), LSNS-R(0.000), RIDDD Initiative(0.03), RIDDD performance(0.000), S-MMSE (0.03), GHQ-
12(0.000), and SSCQ(0.007) 
We fitted a multi-level mixed-effect model with the variables: age, gender, ethnicity, time since 1st attendance 
at memory clinic and whether living with carer as fixed-effect covariates.  























Table A1 Number (%) of participants using services: comparison of the Treatment as Usual 
and intervention groups 
 










Home care worker 35(15.0) 40(17.1) 0.61 35(15.3) 40(17.7) 0.53 
Case/care Manager 13(5.6) 9(3.8) 0.51 12(5.3) 4(9.0) 0.66 
Social Worker 22(9.4) 21(9.0) 1.00 8(3.5) 18(8.0) 0.05* 
Dementia Adviser worker 48(20.5) 32(13.7) 0.07 24(10.5) 26(11.5) 0.77 
Dementia support worker 39(16.7) 42(17.9) 0.81 26(11.4) 39(17.3) 0.08 
Support worker 16(6.8) 13(5.6) 0.70 17(7.4) 20(8.8) 0.61 
Voluntary worker 48(20.5) 53(22.6) 0.65 60(26.3) 52(23.0) 0.45 
Community Mental Health 
Nurse 
61(26.1) 60(25.6) 1.00 25(10.9) 28(12.4) 0.66 
Community District Nurse 29(12.4) 31(13.2) 0.89 30(13.1) 24(10.6) 0.47 
GP 178(76.1) 178(76.1) 1.00 156(68.1) 168(74.3) 0.15 
GP Practice Nurse 109(46.6) 114(48.7) 0.71 125(54.6) 122(54.0) 0.93 
Community Pharmacist 66(28.2) 61(26.1) 0.68 82(35.8) 97(42.9) 0.13 
Psychologist 12(5.1) 8(3.4) 0.49 11(4.8) 13(5.8) 0.40 
Physiotherapist  33(14.1) 25(10.7) 0.33 37(16.2) 34(15.0) 0.80 
Dietician 7(3.0) 3(1.3) 0.34 3(1.3) 5(2.2) 0.36 
Health visitor  0(0.0) 1(0.4) 1.00 0(0.0) 4(1.8) 0.06 
Chiropodist 69(29.5) 76(32.5) 0.55 73(31.9) 87(38.5) 0.14 
Benefits Adviser 13(5.6) 10(4.3) 0.67 21(9.2) 15(6.6) 0.39 
Short-term respite care 1(0.4) 1(0.4) 1.00 3(1.3) 4(1.8) 0.72 
Transport 15(6.4) 18(7.7) 0.72 18(7.9) 22(9.7) 0.51 
Drop-in centre 17(7.3) 10(4.3) 0.23 15(6.6) 16(7.1) 0.85 
Day care centre 10(4.3) 10(4.3) 1.00 0(0.0) 1(0.4) 0.50 
All out-patient visits 164(70.1) 167(71.4) 0.84 145(63.3) 151(66.8) 0.49 
All in patient visits 22(9.4) 36(15.4) 0.07 29(12.6) 38(16.7) 0.24 
In-patient: AE visit 16(6.8) 16(6.8) 1.00 10(4.4) 16(7.1) 0.23 
In-patient - General 
Medical Ward 
7(3.0) 21(9.0) 0.01* 10(4.4) 21(9.3) 0.03* 
In-patient - Geriatric Ward 0(0.0) 3(1.3) 0.25 4(1.7) 0(0.0) 0.12 
In-patient - Surgical Ward 5(2.1) 8(3.4) 0.58 12(5.2) 12(5.3) 1.00 
All aids and adaptations 148(63.2) 151(64.5) 0.85 106(46.3) 61(27.0) 0.00* 
Adaptations 32(13.7) 32(13.7) 1.00 10(4.4) 17(7.5) 0.17 
Equipment 125(53.4) 131(56.0) 0.64 101(44.1) 49(21.7) 0.00* 
Technological aids 60(26.5) 59(25.5) 1.00 47(20.5) 9(4.0) 0.00* 
Memory aid: clocka 44(18.8) 45(19.2) 1.00 61(26.6) 2(0.9) 0.00* 
Memory aid: Medication 
remindera 
81(34.6) 75(32.1) 0.62 89(38.9) 0(0.0) 0.00* 
At each interviewed time point (T1, T2, T3) details of services used over the preceding 3 months were elicited. 
1Baseline (T1); 2Follow up (T2 and T3). 
*p < 0.05, chi-square test 
a Memory aids already received or held by participants in each group; intervention group also received the 






Tables A2-A11 – full model data for each secondary outcome 
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Table A2 full model data for the secondary outcome: CASP 19 (by the patients) coefficients  




95% CI  (B)  z  p-value  
Treatment arm:   
Intervention  
Comparator -0.04 -1.40, 1.32 -0.06 0.95 
































Gender (Female) Male 1.35 0.05, 2.64 2.05 0.04* 
Ethnicity (Non-White) White -0.60 -2.89, 1.68 -0.52 0.61 
≥ 90 days since 1st 
attended Memory Clinic 
< 90 days 0.16 -1.30, 1.62 0.21 0.83 
Living with Primary Carer No 0.64 -0.74, 2.02 0.91 0.36 
*p < 0.05 
CASP19 score varies from 0 to 57; higher scores indicate better QoL. 
Intraclass Correlation Coefficient (ICC) for ‘Trust’ = 0 
We fitted a multi-level mixed-effect model with the covariates in this table as fixed effect and intercept as random 
effects. We treated participants as Level 1 and ‘Trusts’ as Level 2. 
 
Table A3 full model data for the secondary outcome: CASP19 (by the carer) coefficients  




95% CI  (B)  z  p-value  
Treatment arm:   
Intervention  
Comparator -0.07 -1.42, 1.28 -0.10 0.92 
































Gender (Female) Male 0.90 -0.39, 2.19 1.38 0.17 
Ethnicity (Non-White) White -0.57 -2.86, 1.72 0.50 0.62 
≥ 90 days since 1st 
attended Memory Clinic 
< 90 days 0.10 -1.35, 1.54 0.13 0.90 
Living with Primary Carer No -3.74 -5.13, 2.36 -5.30 0.00* 
*p < 0.05 
CASP19 score varies from 0 to 57; higher scores indicate better QoL. 
Intraclass Correlation Coefficient (ICC) for ‘Trust’ = 0.004 
We fitted a multi-level mixed-effect model with the covariates in this table as fixed effect and intercept as random 










Table A4 full model data for the secondary outcome: CDR coefficients  




95% CI  (B)  z  p-value  
Treatment arm:   
Intervention  
Comparator -0.15 -0.82, 0.52 -0.43 0.67 
































Gender (Female) Male -0.32 -0.83, 0.19 -1.24 0.22 
Ethnicity (Non-White) White 0.57 -0.37, 1.51 1.20 0.23 
≥ 90 days since 1st 
attended Memory Clinic 
< 90 days 0.45 -0.13, 1.03 1.53 0.13 
Living with Primary Carer No -0.06 -.062,0.50 0.20 0.84 
*p < 0.05 
CDR scores from 0 to 30; higher is worse or more severe dementia. 
Intraclass Correlation Coefficient (ICC) for ‘Trust’ = 0.02 
We fitted a multi-level mixed-effect model with the covariates in this table as fixed effect and intercept as random 
effects. We treated participants as Level 1 and ‘Trusts’ as Level 2. 
 
Table A5 full model data for the secondary outcome: DEMQOL coefficients  




95% CI  (B)  z  p-value  
Treatment arm:   
Intervention  
Comparator 0.13 -2.29, 2.55 0.11 0.92 
































Gender (Female) Male 2.46 0.11, 4.80 1.20 0.04* 
Ethnicity (Non-White) White -5.60 -9.88, -1.31 2.18 0.01* 
≥ 90 days since 1st 
attended Memory Clinic 
< 90 days 0.40 -2.25, 3.05 1.35 0.76 
Living with Primary Carer No 0.53 -1.97, 3.04 1.28 0.67 
*p < 0.05 
DEMQOL score varies from 28 to 112; higher score indicates better health related QoL. 
Intraclass Correlation Coefficient (ICC) for ‘Trust’ = 0 
We fitted a multi-level mixed-effect model with the covariates in this table as fixed effect and intercept as random 











Table A6 full model data for the secondary outcome: LSNS-R coefficients  




95% CI  (B)  z  p-value  




-2.71, 0.92 -0.96 0.34 
































Gender (Female) Male 0.58 -1.12, 2.29 0.67 0.50 
Ethnicity (Non-White) White 0.64 -2.34,3.63 0.42 0.67 
≥ 90 days since 1st 
attended Memory Clinic 
< 90 days -0.02 -1.93, 1.89 -0.02 0.99 
Living with Primary Carer No 0.88 -0.94, 2.71 0.95 0.34 
*p < 0.05 
LSNS_R: scores from 0 to 60; higher scores indicates more social engagement. 
Intraclass Correlation Coefficient (ICC) for ‘Trust’ = 0 
We fitted a multi-level mixed-effect model with the covariates in this table as fixed effect and intercept as random 
effects. We treated participants as Level 1 and ‘Trusts’ as Level 2. 
 
 
Table A7 full model data for the secondary outcome: RIDDD Initiative coefficients  




95% CI  (B)  z  p-value  
Treatment arm:   
Intervention  
Comparator 0.89 -2.03, 3.82 0.60 0.55 
































Gender (Female) Male 1.07 -1.47, 3.61 0.82 0.41 
Ethnicity (Non-White) White -2.22 -6.92, 2.48 -0.92 0.36 
≥ 90 days since 1st 
attended Memory Clinic 
< 90 days -0.84 -3.74, 2.08 -0.56 0.57 
Living with Primary Carer No -1.78 -4.61, 1.05 -1.23 0.22 
*p < 0.05 
RIDDD initiative: scores from 0 to 60; higher scores show better initiative. 
Intraclass Correlation Coefficient (ICC) for ‘Trust’ = 0.03 
We fitted a multi-level mixed-effect model with the covariates in this table as fixed effect and intercept as random 










Table A8 full model data for the secondary outcome: RIDDD Performance coefficients  




95% CI  (B)  z  p-value  
Treatment arm:   
Intervention  
Comparator -0.78 -3.66, 2.11 -0.53 0.60 
































Gender (Female) Male 0.47 -2.34, 3.29 0.33 0.74 
Ethnicity (Non-White) White -3.38 -8.30, 1.53 -1.35 0.18 
≥ 90 days since 1st 
attended Memory Clinic 
< 90 days -0.10 -3.24, 3.05 -0.06 0.95 
Living with Primary Carer No -1.88 -4.89, 1.12 -1.23 0.22 
*p < 0.05 
RIDDD performance: scores from 0 to 76; higher scores indicate better performance. 
Intraclass Correlation Coefficient (ICC) for ‘Trust’ = 0 
We fitted a multi-level mixed-effect model with the covariates in this table as fixed effect and intercept as random 
effects. We treated participants as Level 1 and ‘Trusts’ as Level 2. 
 
 
Table A9 full model data for the secondary outcome: SMMSE coefficients  




95% CI  (B)  z  p-value  
Treatment arm:   
Intervention  
Comparator -0.20 -1.08, 0.68 -0.45 0.60 
































Gender (Female) Male 0.26 -0.59, 1.12 0.61 0.55 
Ethnicity (Non-White) White -3.51 -5.07, 1.95 -4.41 0.00* 
≥ 90 days since 1st 
attended Memory Clinic 
< 90 days 0.32 -0.66, 1.30 0.65 0.52 
Living with Primary Carer No -0.71 -1.64, 0.23 -1.48 0.14 
*p < 0.05 
SMMSE: scores from 0 to 30; higher scores indicate better cognitive condition. 
Intraclass Correlation Coefficient (ICC) for ‘Trust’ = 0.03 
We fitted a multi-level mixed-effect model with the covariates in this table as fixed effect and intercept as random 











Table A10 full model data for the secondary outcome: GHQ-12 coefficients  




95% CI  (B)  z  p-value  
Treatment arm:   
Intervention  
Comparator -0.38 -1.32, 0.55 -0.81 0.42 
































Gender (Female) Male -1.41 -2.27, -0.55 -3.21 0.001* 
Ethnicity (Non-White) White 0.79 -0.72, 2.30 1.02 0.31 
≥ 90 days since 1st 
attended Memory Clinic 
< 90 days -0.33 -1.29, 0.64 -0.67 0.50 
Living with Primary Carer No 0.14 -0.78, 1.10 0.30 0.76 
*p < 0.05 
GHQ-12: scores from 0 to 60; higher scores indicate better health. 
Intraclass Correlation Coefficient (ICC) for ‘Trust’ = 0 
We fitted a multi-level mixed-effect model with the covariates in this table as fixed effect and intercept as random 
effects. We treated participants as Level 1 and ‘Trusts’ as Level 2. 
 
Table A11 full model data for the secondary outcome: SSCQ coefficients  




95% CI  (B)  z  p-value  
Treatment arm:   
Intervention  
Comparator -0.43 -1.46, 0.59 -0.83 0.40 
































Gender (Female) Male 1.23 0.25, 2.21 2.46 0.01* 
Ethnicity (Non-White) White -1.93 -3.68, -0.17 -2.15 0.03 
≥ 90 days since 1st 
attended Memory Clinic 
< 90 days -0.54 -1.65, 0.57 -0.96 0.34 
Living with Primary Carer No 0.26 -0.80, 1.32 0.49 0.63 
*p < 0.05 
SSCQ: scores from 7 to 35; higher scores indicate show greater dependence. 
Intraclass Correlation Coefficient (ICC) for ‘Trust’ = 0.01 
We fitted a multi-level mixed-effect model with the covariates in this table as fixed effect and intercept as random 











Table A12 ADJUSTED (Multi-level Mixed Model) estimates for primary outcome, BADLS: 
Coefficients (after imputation)  




95% CI  (B)  z  p-value  
Treatment arm:   
Intervention  
Comparator 0.70 -0.92, 2.31 0.85 0.40 
































Gender (Female) Male 0.23 -1.79, 1.34 -0.28 0.78 
Ethnicity (Non-White) White 3.56 0.75, 6.36 2.48 0.01* 
≥ 90 days since 1st 
attended Memory Clinic 
< 90 days -0.92 -2.70, 0.87 -1.01 0.31 
Living with Primary Carer No 0.45 -1.25, 2.14 0.52 0.61 
*p < 0.05 
N =468 at each time point. 
Bristol Activities of Daily Living Scale (BADLS): scores from 0 to 60; higher scores show greater dependence. 
Intraclass Correlation Coefficient (ICC) for ‘Trust’ = 0.01 
We fitted a multi-level mixed-effect model with the variables in the last 5 rows as fixed-effect covariates.  



















Here N’s are 468 for each time point (after multiple imputation). 
 
Figure A1 Mean (95% CI) BADLS SCORES over time by randomly assigned group (after 
imputation) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
